412 related articles for article (PubMed ID: 24386505)
1. Current Understanding on EGFR and Wnt/β-Catenin Signaling in Glioma and Their Possible Crosstalk.
Paul I; Bhattacharya S; Chatterjee A; Ghosh MK
Genes Cancer; 2013 Nov; 4(11-12):427-46. PubMed ID: 24386505
[TBL] [Abstract][Full Text] [Related]
2. Crosstalk between PI3K/AKT/mTOR and WNT/β-Catenin signaling in GBM - Could combination therapy checkmate the collusion?
Daisy Precilla S; Biswas I; Kuduvalli SS; Anitha TS
Cell Signal; 2022 Jul; 95():110350. PubMed ID: 35525406
[TBL] [Abstract][Full Text] [Related]
3. Wnt/β-catenin Antagonists: Exploring New Avenues to Trigger Old Drugs in Alleviating Glioblastoma Multiforme.
Precilla DS; Kuduvalli SS; Purushothaman M; Marimuthu P; Muralidharan AR; Anitha TS
Curr Mol Pharmacol; 2022; 15(2):338-360. PubMed ID: 33881978
[TBL] [Abstract][Full Text] [Related]
4. Reprogramming the immunosuppressive microenvironment of IDH1 wild-type glioblastoma by blocking Wnt signaling between microglia and cancer cells.
Fan D; Yue Q; Chen J; Wang C; Yu R; Jin Z; Yin S; Wang Q; Chen L; Liao X; Peng C; Zhang J; Cao Z; Mao Y; Huang R; Chen L; Li C
Oncoimmunology; 2021 Jun; 10(1):1932061. PubMed ID: 34123575
[TBL] [Abstract][Full Text] [Related]
5. Wnt/β-catenin signaling cascade: A promising target for glioma therapy.
He L; Zhou H; Zeng Z; Yao H; Jiang W; Qu H
J Cell Physiol; 2019 Mar; 234(3):2217-2228. PubMed ID: 30277583
[TBL] [Abstract][Full Text] [Related]
6. β-catenin and Gli1 are prognostic markers in glioblastoma.
Rossi M; Magnoni L; Miracco C; Mori E; Tosi P; Pirtoli L; Tini P; Oliveri G; Cosci E; Bakker A
Cancer Biol Ther; 2011 Apr; 11(8):753-61. PubMed ID: 21321483
[TBL] [Abstract][Full Text] [Related]
7. β-catenin contributes to cordycepin-induced MGMT inhibition and reduction of temozolomide resistance in glioma cells by increasing intracellular reactive oxygen species.
Bi Y; Li H; Yi D; Bai Y; Zhong S; Liu Q; Chen Y; Zhao G
Cancer Lett; 2018 Oct; 435():66-79. PubMed ID: 30081068
[TBL] [Abstract][Full Text] [Related]
8. Wnt/beta-catenin signaling in glioma.
Zhang K; Zhang J; Han L; Pu P; Kang C
J Neuroimmune Pharmacol; 2012 Dec; 7(4):740-9. PubMed ID: 22454041
[TBL] [Abstract][Full Text] [Related]
9. 20(S)-ginsenoside-Rg3 reverses temozolomide resistance and restrains epithelial-mesenchymal transition progression in glioblastoma.
Chen Z; Wei X; Shen L; Zhu H; Zheng X
Cancer Sci; 2019 Jan; 110(1):389-400. PubMed ID: 30431207
[TBL] [Abstract][Full Text] [Related]
10. A novel molecular link between HOXA9 and WNT6 in glioblastoma identifies a subgroup of patients with particular poor prognosis.
Gonçalves CS; Xavier-Magalhães A; Martins EP; Pinto AA; Pires MM; Pinheiro C; Reis RM; Sousa N; Costa BM
Mol Oncol; 2020 Jun; 14(6):1224-1241. PubMed ID: 31923345
[TBL] [Abstract][Full Text] [Related]
11. Treatment of glioblastoma multiforme using a combination of small interfering RNA targeting epidermal growth factor receptor and β-catenin.
Wang K; Park JO; Zhang M
J Gene Med; 2013 Jan; 15(1):42-50. PubMed ID: 23319157
[TBL] [Abstract][Full Text] [Related]
12. Hypoxic Glioma Cell-Secreted Exosomal miR-301a Activates Wnt/β-catenin Signaling and Promotes Radiation Resistance by Targeting TCEAL7.
Yue X; Lan F; Xia T
Mol Ther; 2019 Nov; 27(11):1939-1949. PubMed ID: 31402274
[TBL] [Abstract][Full Text] [Related]
13. Wnt/beta-catenin and PI3K/Akt/mTOR Signaling Pathways in Glioblastoma: Two Main Targets for Drug Design: A Review.
Shahcheraghi SH; Tchokonte-Nana V; Lotfi M; Lotfi M; Ghorbani A; Sadeghnia HR
Curr Pharm Des; 2020; 26(15):1729-1741. PubMed ID: 32003685
[TBL] [Abstract][Full Text] [Related]
14. CUX1 Facilitates the Development of Oncogenic Properties
Feng F; Zhao Z; Zhou Y; Cheng Y; Wu X; Heng X
Front Mol Biosci; 2021; 8():705008. PubMed ID: 34422906
[No Abstract] [Full Text] [Related]
15. AURKA governs self-renewal capacity in glioma-initiating cells via stabilization/activation of β-catenin/Wnt signaling.
Xia Z; Wei P; Zhang H; Ding Z; Yang L; Huang Z; Zhang N
Mol Cancer Res; 2013 Sep; 11(9):1101-11. PubMed ID: 23761169
[TBL] [Abstract][Full Text] [Related]
16. β-Catenin Signalling in Glioblastoma Multiforme and Glioma-Initiating Cells.
Nager M; Bhardwaj D; Cantí C; Medina L; Nogués P; Herreros J
Chemother Res Pract; 2012; 2012():192362. PubMed ID: 22400111
[TBL] [Abstract][Full Text] [Related]
17. RPN2 is targeted by miR-181c and mediates glioma progression and temozolomide sensitivity via the wnt/β-catenin signaling pathway.
Sun J; Ma Q; Li B; Wang C; Mo L; Zhang X; Tang F; Wang Q; Yan X; Yao X; Wu Q; Shu C; Xiong J; Fan W; Wang J
Cell Death Dis; 2020 Oct; 11(10):890. PubMed ID: 33087705
[TBL] [Abstract][Full Text] [Related]
18. Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status.
Chong DQ; Toh XY; Ho IA; Sia KC; Newman JP; Yulyana Y; Ng WH; Lai SH; Ho MM; Dinesh N; Tham CK; Lam PY
BMC Cancer; 2015 Apr; 15():255. PubMed ID: 25886314
[TBL] [Abstract][Full Text] [Related]
19. Attenuation of Tumor Suppressive Function of FBXO16 Ubiquitin Ligase Activates Wnt Signaling In Glioblastoma.
Khan M; Muzumdar D; Shiras A
Neoplasia; 2019 Jan; 21(1):106-116. PubMed ID: 30530053
[TBL] [Abstract][Full Text] [Related]
20. (Pro)renin receptor is crucial for glioma development via the Wnt/β-catenin signaling pathway.
Kouchi M; Shibayama Y; Ogawa D; Miyake K; Nishiyama A; Tamiya T
J Neurosurg; 2017 Oct; 127(4):819-828. PubMed ID: 28059652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
